Encompass Health Corporation Common Stock

Day range

$123.10 – $125.51

Open

$125.47

Prev close

$126.01

Volume

805.86K

Market cap

$12.43B

Shares out

98.65M

P/E

20.07

P/S

2.00

P/B

4.79

P/FCF

30.07

ROE

23.8%

ROA

8.3%

Debt/Equity

1.01

Div yield

0.60%

As of Oct 22, 2026

• Debt activityAug 13, 2026

  On August 13, 2026, Encompass Health Corporation (the "Company") completed the issuance and sale of $100 million in aggregate principal amount of its 5.875% Senior Notes due 2034 (the "Additional Notes"), along with the related guarantees of the Additional Notes by certain of the Company's subsidiaries, in a private offering. The purchase price for the Additional Notes was 98.75% of the aggregate principal amount, resulting in net proceeds to the Company of approximately $96.9 million after deducting the initial purchasers' discount and estimated offering expenses.

• Debt activityJun 1, 2026

  On May 29, 2026, Encompass Health Corporation (the "Company") completed the issuance and sale of $500 million in aggregate principal amount of its 5.875% Senior Notes due 2034 (the "Notes")... The Notes were issued at par for net proceeds of approximately $491.2 million after deducting the initial purchasers' discount and estimated offering expenses.

• Debt activityMay 15, 2026

  Encompass Health Corporation and certain of its subsidiaries entered into a purchase agreement with Wells Fargo Securities, LLC with respect to a private offering by the Company of $500,000,000 in aggregate principal amount of 5.875% senior notes due 2034 (the 'Notes'), along with the related guarantees of the Notes. The Notes Offering is expected to close on or about May 29, 2026.

• Shareholder meetingsMay 11, 2026

  During the Annual Meeting on May 7, 2026, the stockholders of Encompass Health Corporation voted on the following: 1. election of the 10 persons nominated by the Company's board of directors; 2. ratification of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm; and 3. approval of the compensation of the Company's named executive officers. The final voting results for the Annual Meeting were as follows: Proposal 1, election of directors, each of the nominees was elected... Proposal 2, ratification of the appointment of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm, passed... Proposal 3, approval of the compensation of the Company's named executive officers, passed.

• Debt activityMar 10, 2026

  On March 9, 2026, Encompass Health Corporation entered into the Credit Agreement (the '2026 Credit Agreement'), by and among the Company, certain of its subsidiaries, as guarantors, Truist Bank, as administrative agent and collateral agent, and various other lenders. The 2026 Credit Agreement provides for a revolving credit facility of $1 billion, including a $260 million letter of credit subfacility and the Swingline Subfacility.

Days to cover

3.5

Short interest

3.49M

Avg volume

981.87K

As of Sep 30, 2026 · reported to FINRA twice monthly.

• Encompass Health (EHC) is a Top-Ranked Growth Stock: Should You Buy?
  positiveZacks Investment Research· Oct 23, 2026
• Are Investors Undervaluing Encompass Health (EHC) Right Now?
  positiveZacks Investment Research· Oct 21, 2026
• Invest in 2 Madison Mutual Funds for Long-Term Growth
  neutralZacks Investment Research· Oct 21, 2026
• Why Encompass Health (EHC) is a Top Value Stock for the Long-Term
  positiveZacks Investment Research· Oct 9, 2026
• Encompass Health Expands Rehab Footprint With New Maine Hospital
  positiveZacks Investment Research· Oct 7, 2026